Learn more
Order today
Introduced in the U.S. House of Representatives on March 24, 2022, the Equitable Community Access to Pharmacist Services Act, H.R. 7213, would authorize pharmacists to provide care and receive reimbursement for pandemic-related services for our nation’s seniors.
We’re excited to announce the launch of the new APhA Learning Library! This new platform will make it easier than ever for you to get the education you need. Read about some key highlights of our new system.
APhA is committed to facilitating meaningful dialogue between pharmacy management, pharmacy team members, and other stakeholders that result in improved workplaces, well-being, and ability to meet ethical obligations to patient safety.
June 2022 ACIP Immunization Update
Battle Against SDOH & Disparities in Pain Mgmt, Part 1
JFPS 2022
Tools and resources to support your practice
Access Now
APhA’s monthly Pulse on Practice and Policy Open Forum Series creates a platform where all of pharmacy can come together to share perspectives and be informed of key practices and policies impacting the profession.
An APhA member-only resource for pharmacists, pharmacy residents, student pharmacists, pharmacy technicians, and interprofessional health care team members involved in providing transitions of care (TOC) services.
An outline of the key steps to implementing monoclonal antibody therapy administration services in community settings.
View CEO Blog
A letter from Interim CEO Ilisa Bernstein, PharmD, JD, FAPhA, to Dr. Robert Califf, Commissioner of the Food and Drug Administration (FDA), on the importance of pharmacists being allowed to prescribe oral COVID-19 treatments.
View all press releases
WASHINGTON, D.C. – The American Pharmacists Association (APhA) is committed to working with pharmacy teams, medical providers, public health professionals, and other stakeholders following the decision of CDC to expand its recommendations that children aged 6 months and above be vaccinated against COVID-19.
View all news
On Monday, FDA issued a proposed rule aimed at expanding the range of marketed nonprescription drugs available to consumers. The Nonprescription Drug Product with an Additional Condition for Nonprescription Use rule seeks to empower consumers to self-treat certain common conditions and improve public health.
The U.S. House of Representative has passed a broad bipartisan mental health and substance use disorder package known as the Restoring Hope for Mental Health and Well-Being Act of 2022 (H.R. 7666).